Regional chemotherapy for liver-limited metastatic colorectal cancer. Review uri icon

Overview

abstract

  • This review examines the development of hepatic arterial infusion (HAI) of chemotherapy over the past 40 years. Liver metastases are mainly supplied by the hepatic artery, and high levels of intratumoral drug delivery are achievable with the use of HAI. Floxuridine, 5-fluorodeoxyuridine is commonly used, but intra-arterial oxaliplatin and mitomycin- C also have advantages. The dramatic responses observed with HAI plus systemic therapy offer the possibility of resection and cure in select patients. Resectability of liver-limited colorectal cancer metastases should be considered as an endpoint for all patients. Hepatic arterial infusion may be used in palliative, neoadjuvant, and adjuvant settings. Herein, combinations of systemic chemotherapy with HAI are discussed, along with the role of newer cytotoxic and biologic agents. The first-pass extraction of some drugs given by regional perfusion in the liver limits systemic side effects. Toxicity includes catheter-related complications and biliary and gastrointestinal ulcers. The role of HAI therapy for the treatment of unresectable and resectable disease, as well as the use of other regional strategies such as embolization and ablation, are discussed.

publication date

  • July 1, 2008

Research

keywords

  • Antineoplastic Combined Chemotherapy Protocols
  • Colorectal Neoplasms
  • Liver Neoplasms
  • Neoadjuvant Therapy

Identity

Scopus Document Identifier

  • 49149113233

Digital Object Identifier (DOI)

  • 10.3816/CCC.2008.n.032

PubMed ID

  • 18650193

Additional Document Info

volume

  • 7

issue

  • 4